Hirschsprung Disease


Short segment

74–89 %

Long segment

12–22 %

Total colon

4–13 %

Small bowel

3–5 %





Clinical Presentation


HSCR is debilitating and can be fatal. Clinical presentation is highly variable and diagnosis requires a high index of suspicion. Recognizing HSCR is important since surgical management dramatically reduces disease morbidity and mortality.

In the current era, most people with HSCR are diagnosed by 6 months of age [1518], but it remains common to diagnose HSCR in older children and HSCR has been diagnosed in adults up to 73 years of age [19]. HSCR needs to be considered in anyone with severe chronic constipation that began in early infancy, especially if suppositories or enemas are needed for stool passage. However, because constipation is common, affecting up to 35 % of all children [20, 21], and HSCR is rare (1/5000 people), recognizing distinct features that suggest HSCR is important for diagnosis. Furthermore, constipation is only one feature of HSCR. Typical presentations for HSCR include:


Neonatal Intestinal Obstruction


Infants present with marked abdominal distension and bilious emesis. Distension may be severe enough to cause respiratory compromise. Obstruction may occur on the first day of life, but children may also initially have apparently normal bowel movements or “mild constipation” and then present acutely with abdominal distension and vomiting at an older age. Because HSCR requires a high index of suspicion for diagnosis, some infants are hospitalized repeatedly for episodes of presumed “gastroenteritis ” that were actually a manifestation of HSCR-associated intestinal obstruction. The clinical distinction is that gastroenteritis may cause severe vomiting, but does not typically cause as much abdominal distension as HSCR. Vomiting associated with infectious enteritis is also usually followed by diarrhea, whereas intestinal obstruction should be accompanied by reduced stool passage. A distended abdomen occurs in 57–93 % of infants with Hirschsprung disease and bilious emesis occurs in 19–37 % [12, 14, 2224]. Abdominal distension and bilious emesis are also a very common presentation in premature infants with HSCR (96 % and 92 %, respectively). Note that since the ENS forms during the first trimester of pregnancy, incidence of HSCR is similar in term and preterm infants [25].


Neonatal Bowel Perforation


HSCR presents with bowel perforation about 5 % of the time [26, 27] and HSCR causes about 10 % of all neonatal bowel perforations [28]. Symptoms may not be specific and include poor feeding, emesis, abdominal distension, constipation, diarrhea, and lethargy. In two series with 55 cases reported [26, 27], only one child with perforation was more than two months old. Sixty two percent of the perforations were in the cecum or ascending colon and 15 % were in the appendix. Many of the children with bowel perforation had long-segment disease (34 % total colonic aganglionosis, with an additional 23 % having aganglionosis proximal to the splenic flexure). Since long-segment HSCR is less common than short-segment disease (Table 25.2), proximal colon perforation in a young infant should dramatically raise concern for long-segment HSCR. In 55 % of reported cases, the perforation was proximal to the transition zone in ganglion cell containing bowel. In 13 % the perforation was at the transition zone. In 30 %, however, the perforation occurred in aganglionic bowel distal to the transition zone.


Table 25.2
Presenting symptoms in HSCR




























Symptom

Comment

Abdominal distension

Very common in HSCR or anatomic bowel obstruction

Bilious emesis

Common and suggests HSCR or anatomic defects

Constipation

Common in older children with HSCR but also in healthy toddlers and infants

Diarrhea

Foul-smelling, bloody, or “explosive” diarrhea suggests enterocolitis (HAEC)

Delayed meconium

Common in HSCR, but many infants with HSCR do not have delayed meconium

Bowel perforation

Should raise concern for HSCR


Delayed Passage of Meconium


Delayed passage of meconium should suggest the diagnosis of HSCR, but defining HSCR risk in infants with delayed passage of meconium is challenging because the timing of meconium passage reported for healthy infants is variable. In a study of 979 infants older than 34 weeks gestational age in the United States, 97 % passed meconium by 24 h of life, and 99.8 % passed meconium by 36 h of life [29]. Breastfeeding or bottle-feeding did not influence the timing of the first bowel movement, and multivariate analysis demonstrated that only prematurity was a significant predictor of delayed passage of meconium. A similar study in Turkey [30] also demonstrated that 724/743 (97 %) passed meconium by 24 h after birth and 740/743 (99.6 %) passed meconium by the time that they were 48 h old. However, a smaller study in the Netherlands, reported only 56/71 (79 %) of term infants passed meconium by 24 h after birth [31] and in a study of 267 healthy infants in Nigeria, only 92 % passed their first bowel movement by 48 h after birth [32]. In the Nigerian study, 5 % of the infants were preterm, but even if the preterm infants are excluded, the data suggest that at most 97 % of the healthy full-term infants studied passed their first bowel movement by the time they were 48 h old. Excluding premature infants from the analysis is important since prematurity predisposes to delayed passage of meconium. A study of 611 infants reported that only 57 % of infants less than 29 weeks EGA, 66 % of infants between 29 and 32 weeks EGA, and 80 % of infants between 32 and 37 weeks EGA [33] passed meconium by the end of their “second calendar day” and 1 % of premature infants did not pass meconium until after day of life 9.

In children with Hirschsprung disease, delayed passage of meconium is much more common than in healthy infants. Nonetheless, up to 50 % of children with HSCR pass meconium by 48 h after birth [22, 34, 35], so passage of meconium within 48 h of birth does not exclude a diagnosis of HSCR.


Chronic Severe Constipation


HSCR causes constipation , but constipation unrelated to HSCR is very common (e.g., 25 % of healthy children) and HSCR is rare, so constipation alone usually does not indicate HSCR. “Severe” constipation and constipation beginning within the first few months of life does increase concern for HSCR and the likelihood of disease. For example, in one study, rectal biopsy was performed on all children over a year of age who were referred to a specialty center for consultation and who had constipation refractory to more than 6 months of medical management. Nineteen out of 395 biopsies demonstrated HSCR (5 %), a 250-fold increased risk compared to the population prevalence of HSCR (1/5000) [36]. Constipation in isolation also appears to be an uncommon presentation of HSCR in infants. In particular, the wide range of normal bowel movement frequency in healthy infants makes it difficult to use constipation as the only indication to evaluate for HSCR. In a study of 911 healthy children in Turkey [30] between 2 and 12 months of age, mean stool frequency was once a day, but at 2 months of age, stool frequency varied from once a week to eight times per day.


Abdominal Distension Relieved by Rectal Stimulation or Enema


In children with HSCR, rectal exam or other forms of rectal stimulation may cause a sudden “explosive” release of intraluminal contents and relieve abdominal distension. This is uncommon in other conditions and should raise concern about HSCR. Rectal exam is, however, not otherwise useful in identifying children with HSCR. In particular, “anal tone” is not a reliable indicator of disease.


Enterocolitis


Defining when children have enterocolitis presents its’ own challenges (see below for symptoms), but enterocolitis is a dangerous and common presentation for HSCR. When enterocolitis occurs, children with HSCR have diarrhea instead of constipation.


Who Should Be Biopsied to Evaluate for Hirschsprung Disease?


Rectal biopsy is the “gold standard” diagnostic test for HSCR (see below). Unless another diagnosis is evident, children with the following clinical presentations should undergo rectal biopsy to evaluate for Hirschsprung disease:


  1. 1.


    Neonates with significant abdominal distension, especially in combination with bilious vomiting or delayed passage of meconium

     

  2. 2.


    Neonates with bowel perforation

     

Also consider rectal biopsy for Hirschsprung disease in children with:


  1. 1.


    Neonatal bloody diarrhea. Given the low incidence of infectious enteritis in breastfed or formula-fed neonates, bloody diarrhea in neonates is concerning for HSCR-associated enterocolitis (see below). Note, however, that many infants have small streaks of blood in the stool without diarrhea or other symptoms of Hirschsprung disease, and hematochezia alone does not warrant rectal biopsy.

     

  2. 2.


    Healthy-appearing full-term infants with delayed passage of meconium even in the absence of other symptoms. Since Hirschsprung disease occurs in 1:5000 infants, but delayed passage of meconium for more than 48 h after birth probably happens in at least 1:1000 healthy infants, most children (i.e., >80 %) who have delayed passage of meconium for 48 h will not have HSCR, but the risk of HSCR is probably 5–20 %. Given the risks associated with untreated HSCR, I usually recommend biopsy in this setting. Assuming that 97 % of healthy full-term infants pass meconium by 24 h of life, only about 1:150 children with passage of meconium >24 h after birth, but <48 h after birth will have HSCR. The value of rectal biopsy in this setting is more questionable, unless other symptoms of HSCR are present.

     

  3. 3.


    Young children with constipation refractory to oral medication. Constipation beginning after a year of age is rarely due to HSCR. Constipation that improves dramatically with oral medication is also unlikely to be due to HSCR. Remember too that the common form of functional constipation that occurs in toddlers may be challenging to treat, usually requiring complete disimpaction and daily maintenance medicine for relief of symptoms, so it can be challenging to know if toddlers are truly “refractory to oral medication.”

     


Red Flags (Conditions That Should Raise Suspicion for HSCR)





  1. 1.


    Constipation with episodes of abdominal distension or vomiting. Constipation does not cause vomiting, but many disorders cause both vomiting and reduced bowel movement frequency including HSCR.

     

  2. 2.


    Growth failure. This is a common feature of untreated HSCR.

     

  3. 3.


    Trisomy 21. HSCR occurs in 1–2 % of children with Down syndrome so HSCR should be more readily suspected in children with trisomy 21 [3739].

     

  4. 4.


    The presence of additional major anomalies also increases the likelihood of HSCR, but remember that most children with HSCR (>70 %) do not have other medical problems [18, 40, 41].

     

Given the diverse presenting symptoms of HSCR, it remains difficult to decide who to evaluate. The more “classic” features of HSCR that are present, the more likely the child has HSCR. Given the high morbidity and mortality in untreated HSCR, evaluation for HSCR should be performed in many children who do not end up having this disease to avoid missing this potentially life-threatening medical problem.


Diagnostic Strategies


HSCR by definition means that affected individuals do not have ganglion cells in the distal bowel. Rectal biopsy is therefore required to make the diagnosis and is considered the “gold standard” approach [42]. A number of other strategies for diagnosing HSCR are used, but each has problems.


Rectal Suction Biopsy


This is a simple procedure taking only a few minutes using an instrument designed to take small pieces of the rectal mucosa (e.g., Noblett or rbi2 instrument) to reduce the risk of bowel perforation or hemorrhage [43]. Because there are no sensory nerve endings that respond to cutting in the area of the rectum where the biopsies are obtained, sedation and pain medicines are not required, but sedation is sometimes used in older children. Biopsies should be obtained at 2–3 cm from the dentate line (i.e., the transition between rectal and squamous mucosa) because there is a physiological submucosal aganglionosis in the terminal rectum. From a practical standpoint, however, some authors advocate obtaining biopsies at multiple levels (e.g., 1–3 cm from the dentate line) because precise positioning of the biopsy can be difficult. Biopsy tissues obtained is sectioned, stained, and examined by a pathologist to identify ganglion cells. There is some controversy about the optimal staining method, but hematoxylin and eosin and acetylcholinesterase are commonly used techniques [42, 43]. Calretinin staining might improve diagnostic accuracy [44, 45], but data are still limited. A meta-analysis analyzing data from 993 patients indicated that the mean sensitivity of rectal suction biopsy for HSCR is 93 %, and the mean specificity is 98 % [46]. A more recent manuscript documents 935 cases of HSCR diagnosed by rectal mucosal biopsy (a total of 19,365 biopsies in 6615 children) with no false-positive or false-negative diagnoses (i.e., 100 % sensitivity and specificity) [47]. Serious bleeding and bowel perforation are uncommon with rectal suction biopsy, but can occur. One series of 1340 biopsies [48] reported three bowel perforations (0.2 %), one death (0.07 %), and three rectal hemorrhage (0.2 %) requiring blood transfusion. More recent studies also document low but nonzero rates of serious bleeding or bowel perforation (0 complication in 297 children [49], 0 complication in 88 infants [50], and two episodes of bleeding requiring transfusion (0.7 %) plus one episode of rectal perforation and sepsis (0.035 %) in 272 children) [51]. The most common problem with rectal suction biopsies, however, is that they are so small that they are “inadequate” 6–26 % of the time, requiring repeat biopsy to make a diagnosis [49, 51, 52]. The more recently introduced rbi2 biopsy instrument appears to give a lower frequency of “inadequate specimens” [50] and may give larger biopsies. It is not yet clear if there are also more complications (bleeding or bowel perforation) using the new instrument since large cohort studies have not been published.


Anorectal Manometry


This method tests for the rectoanal inhibition reflex using a small balloon attached to a tube inserted into the rectum [46]. This reflex is absent in children with HSCR. Sensitivity and specificity of anorectal manometry are 91 % and 94 %, respectively, but this test is not required to diagnose HSCR [46]. The equipment needed to do th is test is also expensive, and significant experience is needed to evaluate results in infants less than a year of age, so the test is not widely available. Recently developed high-resolution anorectal manometry does not appear to provide increased sensitivity or specificity for HSCR diagnosis (89 % and 83 %, respectively, compared to rectal suction biopsy) [53].


Contrast Enema


This is an X-ray test where images are obtained as contrast is infused into the colon via the anal canal to look for evidence of the distal bowel contraction that occurs in areas of aganglionosis. The change in bowel caliper between contracted distal aganglionic bowel and more dilated ganglion cell containing bowel is called the “transition zone” and suggests HSCR. Although contrast enema may have value in planning the surgical approach to HSCR, the radiographic and anatomic transition from aganglionic to ganglion cell containing bowel may not be in the same location. Note too that in total colonic HSCR, there is no colon transition zone. Furthermore, the sensitivity (70 %) and specificity (50–80 %) are considerably lower using contrast enema for HSCR diagnosis than other methods [24, 46]. The role of contrast enema in HSCR diagnosis therefore remains a matter of debate.


Full-Thickness Rectal Biopsy


Deeper biopsies can be performed by a surgeon under general anesthesia if the diagnosis remains uncertain after rectal suction biopsy. This method should unambiguously identify enteric neurons if they are present.


Epidemiology/Genetics Overview


HSCR is a multigenic disorder that affects approximately 1/5000 infants. At least 11 specific gene defects are associated with HSCR (RET, GDNF, NRTN, SOX10, EDNRB, EDN3 ECE1, ZFHX1B, PHOX2B, KIAA1279, TCF4; reviewed in Chap. 18). For short-segment disease, there is an approximately 4:1 male to female ratio, but for total colonic aganglionosis, the male to female ratio is near 2:1. HSCR has been reported throughout the world in many ethnic groups. There are geographic and racial differences described in HSCR incidence, but these data are difficult to evaluate. Most reports have not been replicated over extended time periods and the difficulty in HSCR diagnosis increases uncertainty in interpreting regional data. Furthermore, it is often not possible to determine from large-scale epidemiological studies the number of affected individuals who share mutations by common descent, so data may be skewed by families with multiple affected members such as has been described in some Mennonite communities [54]. HSCR incidence per 10,000 live births in California was reported as 1.0, 1.5, 2.1, and 2.8 for Hispanics, Caucasian-Americans, African-Americans, and Asians, respectively [55]. HSCR incidence was reported as 1.4 per 10,000 in Denmark, 1.8–2.1 per 10,000 in Japan [11], and 2.3 per 10,000 in British Columbia [56]. Considerably higher rates of HSCR are reported in some small geographic areas or ethnic groups. For example, HSCR incidence is 2.9 per 10,000 in Tasmania [57], 5.6 per 10,000 for native Alaskans [58], 7.3 per 10,000 in Pohnpei State in the Federated States of Micronesia [59], and 5.6 per 10,000 in Oman [60]. In Oman, rates of consanguinity are reported to be high (75 % first or second cousins), but this was not reported in other areas. The European registry (EUROCAT – European Registration of Congenital Anomalies and Twin s) also describes striking differences between reporting regions, but ascertainment for HSCR is challenging, and it seems unlikely that the 31 reporting regions use the same ascertainment strategies [18]. Nonetheless, founder effects within populations, nutritional factors, or environmental toxins may account for these differences in HSCR incidence.

Recurrence risk for siblings of children with HSCR is dramatically elevated compared to the general population, but HSCR is a non-Mendelian disease, and risk varies from 1:3 to 1:100 [6, 61] depending on the sex of the proband and their extent of aganglionosis. Because female sex protects against HSCR and because long-segment disease implies more serious genetic risk than short-segment disease, male siblings of females with long-segment HSCR have a 33 % chance of HSCR, while new sisters have only a 9 % risk. Siblings of males with long-segment HSCR have a recurrence risk of 17 % and 13 % in new brothers and sisters, respectively. For a male proband with short-segment HSCR, the risk of recurrence is 5 % in male siblings, but only 1 % in female siblings. For a female proband with short-segment disease, recurrence risk is 5 % and 3 % for new male and female siblings, respectively. These complex epidemiologic and recurrence risk data are a direct reflection of the genetic underpinnings of HSCR. While these “average” data are helpful in discussions with families, far better estimates of HSCR recurrence risk could theoretically be obtained using modern molecular genetic techniques.


Associated Medical Problems


HSCR is an isolated anomaly in ~70 % of affected individuals, but ~30 % of children with HSCR have additional birth defects, including the ~12 % of children with HSCR who have chromosomal anomalies [18, 35, 41, 56, 6264]. A very wide range of additional defects have been reported in children with HSCR. The most common defects are congenital heart disease, sensory neural problems, kidney and urinary tract, and skeletal anomalies. Many different chromosomal defects have been described in people with HSCR, but trisomy 21 is by far the most common. There are also >30 genetic syndromes associated with HSCR (reviewed in [6, 65]). A few HSCR-associated syndromes are summarized in Table 25.3.


Table 25.3
Selected HSCR-associated syndromes


























































Syndrome name

Genetic defect

Comments

MEN2A = multiple endocrine neoplasia 2A

RET mutation in codons 609, 611, 618, or 620

~2 % of children with HSCR may have MEN2A RET mutations

FMTC = familial medullary thyroid carcinoma

20–30 % of families with Ret 609, 611, 618, or 620 mutations have members with both FMTC and HSCR

Down syndrome

Trisomy 21

1–2 % of children with trisomy 21 have HSCR

2–10 % of children with HSCR have Down’s

WS4 = Waardenburg syndrome

WS4A = EDNRB

9 % of children with HSCR have WS4

WS4C = SOX10

Syndrome includes HSCR, deafness, and pigmentary abnormalities

CCHS = congenital central hypoventilation syndrome

PHOX2B

20 % of children with CCHS have HSCR

0.5–1.5 % of children with HSCR have CCHS

MWS = Mowat-Wilson syndrome

ZFHX1B

60 % of children with MWS have HSCR

6 % of children with HSCR have MWS

Syndrome includes HSCR, intellectual disability, epilepsy, dysmorphic facial features, and brain and heart defects

Goldberg-Shprintzen megacolon syndrome

KIAA1279

Syndrome includes HSCR, intellectual disability, dysmorphic facial features, and brain and heart defects

CHH = cartilage-hair hypoplasia syndrome

RMRP

Syndrome includes short stature (dwarfism), other skeletal defects (short limbs), fine sparse hair, and immunodeficiency

~9 % of children with CHH have HSCR

CHH is rare in children with HSCR


Surgical Management


Although Harald Hirschsprung first described children with the disease that now bears his name in 1886 [66], the pathophysiology of HSCR and management strategies remained unknown until the first successful surgical approach was described in 1948 [67]. There are many modifications of the original pull-through surgery, but the most common procedures today are the Swenson, Duhamel, and Suave endorectal techniques with modification of surgical approaches for total colonic HSCR [1, 14, 68]. For each of these procedures, intraoperative biopsies are obtained to determine the extent of aganglionosis. The Swenson procedure involves complete resection of the aganglionic bowel with reanastomosis of ganglion cell containing bowel to a 1–2 cm rectal cuff. In the Duhamel modification, ganglion cell containing bowel is brought through the retrorectal space and anastomosed to a segment of aganglionic rectum using a side-to-side anastomosis. In the Suave procedure as modified by Boley, the rectal mucosa and submucosa are removed and the ganglion cell containing bowel is pulled through a muscular cuff of distal aganglionic bowel and then attached within one cm of the anal verge. There are innumerable studies of surgical outcome, but few large-scale systematic comparisons are available [69], so it remains unclear that one procedure is better than another. Over the past decade, there have been three major changes in surgical management. These include laparoscopic surgery, transanal surgery, and increased use of one-step surgical procedures [12, 7073]. A recent analysis of transanal versus transabdominal surgery suggests that the children who had transanal endorectal pull-through procedures for HSCR had fewer complications and lower rates of enterocolitis [17]. A comparison of single versus multistage pull-through surgery also suggested that children with single-stage surgery tend to do better, but a subgroup of children who are seriously ill with HSCR may do best with multistep surgery [74].


Cost for Initial Management


For children with HSCR, initial hospitalization costs average $100,000 and the hospital stay averages almost a month [75]. Taking into account HSCR incidence and birth rates, estimated cost for initial care of children with HSCR in the United States is at least $86 million/year. This cost estimate does not include the expense of lost work time or other expenses families encounter while caring for an ill child. Estimates also do not include the cost of ongoing care after the initial hospitalization, which in some cases may be significant, especially in children with enterocolitis. For children with aganglionosis extending into the small bowel, long-term parenteral nutrition also adds dramatically to cost and disease morbidity. Finding new ways to treat or prevent HSCR therefore remains desirable.


Enterocolitis


Hirschsprung disease-associated enterocolitis (HAEC) is common, can occur at any time before or after surgery, and is the most frequent cause of death in infants and children with HSCR [7678]. Death from HAEC occurs because HSCR predisposes to bacterial translocation into the bloodstream that leads to sepsis. Nonetheless, recognizing HAEC is difficult and until recently there was no standard clinical definition for HAEC. In 2009 a consensus of expert surgeons and gastroenterologists developed a systematic scoring system to identify children with HSCR [79]. Components of the score include “explosive” diarrhea, foul-smelling diarrhea, or bloody diarrhea. Additional components include abdominal distension, explosive discharge of gas and stool with rectal exam, reduced peripheral perfusion, lethargy, and fever. Radiographic findings include multiple air fluid levels, distended loops of bowel, sawtooth and irregular mucosal lining, pneumatosis, and rectosigmoid cutoff sign with the absence of distal air. Laboratory finding include leukocytosis and a left shift. Many of these features are also listed as presenting symptoms for HSCR because HAEC is common in children with HSCR, especially before surgery.

The reason that children with HSCR develop HAEC is not clear, but enterocolitis does not occur in children with “severe” functional constipation. Possible predisposing factors for HAEC in children with HSCR include residual partial bowel obstruction, defects in epithelial integrity, or abnormalities in the mucosal immune system [78, 80]. Partial obstruction may result from stricture or from intestinal dysmotility causing increased intraluminal pressure and possibly changes in gut flora [81]. Epithelial dysfunction may occur because enteric neurons and glia support normal bowel epithelial cell function and mucin production [8290]. Problems with intestinal immunity may occur because the ENS directly regulates the adaptive and innate intestinal immune system [9193]. This includes effects on diverse immune system cells by the ENS neurotransmitters vasoactive intestinal peptide (VIP ), neuropeptide Y (NPY), calcitonin gene-related peptide (CGRP), acetylcholine, substance P, and serotonin [94]. Furthermore, some genes that are mutated in children with HSCR have roles in the immune system. For example, RET is important for Peyer’s patch formation [95] and immune cell function [96, 97], while EDNRB is important for normal spleen development [98]. Recent work also highlights close interaction between the ENS and macrophages in the muscle layers of the bowel [99, 100]. Given the diverse genetic underpinnings of HSCR and important roles for the ENS controlling intestinal motility, blood flow, epithelial function and immune system function, it seems likely that diverse mechanisms lead to HAEC.

Optimal methods to treat or prevent HAEC are not yet known. Current treatment includes bowel rest, nasogastric tube drainage, intravenous fluids, decompression of dilated bowel via rectal dilation and/or rectal irrigation with normal saline, and the use of broad-spectrum antibiotics [80]. Routine rectal irrigation [101] and long-term metronidazole treatment in children at high risk of enterocolitis may further reduce the frequency of HAEC episodes. Probiotics might also reduce HAEC frequency [102], but beneficial effects are not consistently reported [103] suggesting the need for more investigation. Because HAEC is potentially fatal, it is critical that families understand symptoms of enterocolitis and that plans are in place for prompt treatment should these symptoms arise.


Long-Term Outcome


HSCR is a deadly disease, but outcome with modern surgical methods and improved medical management strategies is dramatically better than in the past. Nonoperative management leads to very high mortality rates (e.g., >50–80 %), and reports from the 1970s describe mortality rates of 25–35 % [14, 104] even with surgical treatment. HSCR death rates today remain about 2–6 % despite modern therapy in large part attributable to enterocolitis [10, 11, 35, 105, 106]. Enterocolitis occurs commonly both before and after surgery for HSCR (25–45 % of children) [17, 75, 107, 108]. Long-term outcome even years after surgery also remains less than ideal with only 45–89 % having normal bowel function. Many individuals continue to have soiling (4–29 %), constipation (3–22 %), or permanent stomas (7–10 %) [109111]. Normal bowel function is even less common in children with Down syndrome (34 %). Bowel function appears to improve as children get older with “normal” continence in 58 % at 5–10 years after surgery, 68 % at 10–15 years after surgery, and 89 % at 15–20 years after surgery in one study [111]. In this analysis, however, 7 % had marked limitation in their social life 5–10 years after surgery, but this problem improved as children became older.

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Aug 29, 2017 | Posted by in GASTROENTEROLOGY | Comments Off on Hirschsprung Disease

Full access? Get Clinical Tree

Get Clinical Tree app for offline access